Irreversible myocardial injury attenuates the benefits of sacubitril/valsartan in heart failure patients

Despite the established benefits of angiotensin receptor-neprilysin inhibitor (ARNI) in heart failure with reduced ejection fraction (HFrEF) across various etiologies, there are controversies regarding the effects of ARNI in patients with irreversible myocardial injury. The aim of this study is to investigate the impact of irreversible myocardial injury on the benefits of ARNI treatment in patients with HFrEF, consisted of both ischemic and non-ischemic etiologies.

Source: International Journal of Cardiology - November 27, 2023 Category: Cardiology Authors: Hong-Mi Choi, In-Chang Hwang, Hye Jung Choi, Yeonyee E. Yoon, Hyun-Jung Lee, Jun-Bean Park, Seung-Pyo Lee, Hyung-Kwan Kim, Yong-Jin Kim, Goo-Yeong Cho Source Type: research